Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that selectively stimulates GH release through the ghrelin receptor. It has a long history in the research-peptide and wellness market, often paired with CJC-1295 in 'GH-restoration' protocols at peptide clinics.
The regulatory picture matches the broader research-peptide pattern. Its nomination for 503A compounding was withdrawn, it has been in the FDA's Category 2 for 503B outsourcing facilities since September 2023, and it was on the ProPublica-reported list of injectable peptides covered by the FDA's 2023 effective ban.
In October 2026 a Victorian coroner in Australia found that actor Richard Norton, 75, died from complications of injecting ipamorelin and CJC-1295 made by a licensed compounding pharmacy, after taking more than his prescribed dose, and asked the TGA to consider tighter restrictions. Ipamorelin was not one of the six peptides in HHS's October 2026 compounding policy. Our safety explainer covers the finding and the human evidence.
Clinical evidence for advertised wellness claims (anti-aging, body composition, recovery) remains thin. See #cjc-1295 and #sermorelin for adjacent tags.
The San Francisco Standard reported on a black-tie, alcohol-free party hosted by the startup accelerator Haus Fund aboard the SS Jeremiah O'Brien at Pier 35, where guests signed waivers and sampled U.S.-made sublingual strips containing CJC-1295 and ipamorelin, a GHK-Cu cream, and products from Afterglow Science, whose strips include tirzepatide and a BPC-157, TB-500, and GHK-Cu blend. Guests received stickers reading "Buy American peptides"; Dr. Jordan Shlain, cofounder of a longevity medicine conference, said good manufacturing is no substitute for evidence, and the article notes little research supports claims that sublingual peptides absorb as well as injections.
After a Victorian coroner linked actor Richard Norton's death to injected CJC-1295 and ipamorelin, independent MP Dr Monique Ryan renewed her call for the Health Minister to refer telehealth and online prescribing to the House Health Committee, Retail Pharmacy reported. She first wrote to the minister in August; the inquiry she wants would examine companies that combine telehealth, pharmacy, and retail, the routes that let unapproved peptides be prescribed and compounded, and gaps between the TGA, AHPRA, and the states. "This inquiry is about protecting good telehealth from profit-driven prescribing, not winding it back," she said.
ABC News reported that Victorian coroner David Ryan found Richard Norton, 75, died at Melbourne's Alfred Hospital on March 30, 2025, from complications of injecting the unapproved peptides CJC-1295 and ipamorelin, which a licensed Queensland compounding pharmacy made for him. Norton had told a clinic nurse he was injecting double his prescribed dose and collapsed hours later after another injection. Ryan recommended the Therapeutic Goods Administration review the peptides' benefits and risks and consider further restrictions; the ABC called it believed to be Australia's first confirmed death from unapproved peptide use.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.